Company Overview and News

 
CANADA STOCKS-TSX climbs, led by financials, Poloz comments

42m reuters
April 23 (Reuters) - Canada’s main stock index rose on Monday, as financial shares gained and after Bank of Canada chief showed comfort with inflation running above the central bank’s 2 percent target.
Upvote Downvote

 
CANADA STOCKS-TSX higher as financial stocks gain

1h reuters
Canada’s main stock index opened higher on Monday, led by gains in financial shares and as Bank of Canada chief showed comfort with inflation running above the central bank’s 2 percent target.
Upvote Downvote

 
Annual Financial Report and Notice of AGM

2018-04-20 globenewswire
The information set out in this announcement is the Company's full unedited annual financial report (audited) for the year ended 31 December, 2017 (the "AFR"). The AFR is expected to be printed and posted to all shareholders within April, 2018 and the Company will make a further announcement once the AFR has been uploaded to the Company's website and to the National Storage Mechanism, www.morningstar.
Upvote Downvote

 
CANADA STOCKS-TSX opens higher as financials, Rogers Communications offset energy

2018-04-20 reuters
April 20 (Reuters) - Canada’s main stock index opened higher on Friday as gains in financial stocks and shares of Rogers Communications offset declines in energy companies.
Upvote Downvote

 
CANADA STOCKS-TSX slightly lower as financials, consumer cyclicals offset oil boost

2018-04-19 reuters
April 19 (Reuters) - Canada’s main stock index was slightly lower on Thursday, as declines in financials and consumer cyclical companies weighed, but strong gains in energy shares that benefited from a rally in oil prices kept further losses in check.
Upvote Downvote

 
CANADA STOCKS-TSX little changed as telecom, financials offset oil rally's boost

2018-04-19 reuters
April 19 (Reuters) - Canada’s main stock index opened little changed on Thursday as losses in telecom and financials companies curbed strong gains in energy shares benefiting from surging oil prices.
Upvote Downvote

 
CANADA STOCKS-TSX jumps with oil prices, rate hike prospects boost banks

2018-04-18 reuters
April 18 (Reuters) - Canada’s main stock index rose for the fifth day in a row on Wednesday, to hit a near-one month high, as energy stocks gained with oil prices and banks moved higher after the Bank of Canada struck a more hawkish tone on the future of interest rates.
Upvote Downvote

 
CANADA STOCKS-TSX near 4-week high as energy, materials gain

2018-04-18 reuters
April 18 (Reuters) - Canada’s main stock index rose sharply after opening at a near one-month high on Wednesday, helped by gains in energy and material companies, and after the Bank of Canada issued an optimistic economic growth outlook.
Upvote Downvote

 
CANADA STOCKS-TSX gains on higher oil prices; rate decision awaited

2018-04-18 reuters
April 18 (Reuters) - Canada’s main stock index opened at a near one-month high on Wednesday, helped by gains in energy companies on higher oil prices and a rise in financial stocks ahead of Bank of Canada’s interest rate decision.
Upvote Downvote

 
CANADA STOCKS-TSX gains on upbeat data, rising energy stocks

2018-04-17 reuters
April 17 (Reuters) - Canada’s main stock index rose on Tuesday, helped by upbeat manufacturing data and as energy shares rose alongside oil prices.
Upvote Downvote

 
CORRECTED-CANADA STOCKS-TSX rises amid broad rally led by financials

2018-04-17 reuters
(Corrects first paragraph to show a decision on interest rates is expected, not an increase in rates)
Upvote Downvote

 
WestJet CEO Vows to Win Back Investors With Discount Unit, 787s - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

1
CANADA STOCKS-TSX gains as Syria fears fade; financials rise

2018-04-16 reuters
April 16 (Reuters) - Canada’s main stock index opened higher on Monday, driven by gains in financial shares and waning fears of an escalating conflict in Syria following the weekend’s U.S.-led air strikes.
Upvote Downvote

 
Why International Diversification Benefits Canadian Investors

2018-04-13 blackrockblog
Our annual ETF Investor Pulse survey shows that Canadian investors invest three-quarters of their portfolios domestically, exhibiting a large "home bias" - the tendency to prefer domestic over global securities. Although this bias is not unique to Canada, the implications are greater for Canadian investors because the domestic equity market is smaller, narrower, and contains large sector tilts. In our view, geographic diversification is as important as asset class diversification for Canadian investors.
Upvote Downvote

 
Why this $100-billion fund manager thinks the TSX is about to bounce back

2018-04-11 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...